English, Article edition: The Management of Women at High Risk of Experiencing Hereditary Breast and Ovarian Cancer: The Lahey Guidelines Kevin S. Hughes; Constance A. Roche; Timothy Whitney; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/92623
Physical Description
  • article
Language
  • English

Edition details

Title
  • The Management of Women at High Risk of Experiencing Hereditary Breast and Ovarian Cancer: The Lahey Guidelines
Author
  • Kevin S. Hughes
  • Constance A. Roche
  • Timothy Whitney
  • Robert McLellan
Physical Description
  • article
Notes
  • Most breast and ovarian cancers occur sporadically, but an estimated 5 to 10% of cases occur in women with hereditary predisposition to these cancers. Two genes, BRCA1 and BRCA2, have been identified, which, when altered, are thought to be responsible for most cases of hereditary breast and ovarian cancer. Testing for mutations in these genes is now available for women who are at risk. At present, only a small percentage of women have been tested, and identification of high risk women is dependent on pedigree analysis and application of empiric models. In the general population, the level of risk of hereditary cancer ranges from nonexistent to highly likely. A disease management approach requires identification of the level of risk of each individual in the population, and the development of a specific management strategy of screening and consideration of chemoprevention and prophylactic surgery commensurate with risk. Therefore, risk identification takes on an important role in the allocation of health resources. This article presents an approach to categorising women who are at increased risk of experiencing hereditary breast or ovarian cancer, whether or not testing is accepted or feasible. An evidence-based approach to screening and measures for prevention are outlined according to level of risk. Occasions when genetic testing would appreciably enhance decisions regarding management are noted. Clinically useful guidelines for risk assessment and management are intended to reduce the incidence of and morbidity associated with hereditary breast and ovarian cancer. Ongoing research with regard to clinical outcomes of carriers of the BRCA1 or BRCA2 mutation will help refine these strategies.
  • Antineoplastics, Breast cancer, Breast cancer, Mastectomy, Ovarian cancer, Ovarian cancer, Ovariectomy, Pharmacoeconomics, Practice guideline, Tamoxifen
  • RePEc:wkh:dmhout:v:7:y:2000:i:4:p:201-215
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment